Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Inventiva ( (IVA) ) has provided an announcement.
On November 6, 2025, Inventiva announced the total voting rights and shares forming its share capital as of October 20, 2025. The company reported 145,951,274 shares outstanding with 158,653,570 gross voting rights and 158,594,019 net voting rights. This update is crucial for stakeholders as it informs them about the company’s governance structure and potential influence at shareholder meetings.
The most recent analyst rating on (IVA) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Inventiva stock, see the IVA Stock Forecast page.
Spark’s Take on IVA Stock
According to Spark, TipRanks’ AI Analyst, IVA is a Neutral.
Inventiva’s overall stock score is primarily impacted by its poor financial performance, characterized by persistent losses and negative margins. The technical analysis further indicates a bearish trend, while the valuation metrics highlight ongoing financial challenges. The absence of earnings call data and corporate events does not influence the score.
To see Spark’s full report on IVA stock, click here.
More about Inventiva
Inventiva is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies for treating patients with MASH, a chronic liver disease. The company is publicly listed on Euronext Paris and the Nasdaq Global Market.
Average Trading Volume: 159,852
Technical Sentiment Signal: Buy
Current Market Cap: $616.8M
See more insights into IVA stock on TipRanks’ Stock Analysis page.